Roche and Genentech have ironed out their differences and announced this morning a friendly deal in which Roche will be buying the 44 percent of Genentech it doesn't already own for $95 a share, reports Agence France-Presse.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.